Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (38)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Day, C. J.
Right arrow Articles by Adu, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Day, C. J.
Right arrow Articles by Adu, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2002) 17: 2011-2013
© 2002 European Renal Association-European Dialysis and Transplant Association

Preliminary Communication

Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome

Clara J. Day, Paul Cockwell1, Graham W. Lipkin1, Caroline O. S. Savage1, Alexander J. Howie2 and Dwomoa Adu1,

New Cross Hospital, Wolverhampton, 1 Department of Nephrology, Queen Elizabeth Hospital, Birmingham and 2 Department of Pathology, University of Birmingham, Birmingham, UK

Abstract

Background. A small proportion of patients with initially steroid-sensitive nephrotic syndrome relapse frequently, despite treatment with cyclophosphamide and/or cyclosporin. We investigated the efficacy of mycophenolate mofetil (MMF) in this group.

Methods. Seven patients with nephrotic syndrome due to minimal change nephropathy (MCN) or classical focal segmental glomerulosclerosis (FSGS) who had suffered multiple relapses over many years despite treatment with several different agents were commenced on MMF 1 g twice daily, together with a reducing dose of corticosteroids.

Results. Six patients went into complete remission and the seventh into partial remission. At 1 year, five remained in complete remission. The median (range) serum albumin concentration rose from 19 g/l (16–42 g/l) pre-MMF to 42 g/l (25–45 g/l) after 12 months (P=0.023), and the median (range) dose of prednisolone fell from 40 mg/day (30–60 mg/day) to 7.5 mg/day (0–40 mg/day) at 12 months (P=0.0008).

Conclusion. MMF appears to be of benefit in the treatment of multiply relapsing nephrotic syndrome caused by MCN or FSGS. Controlled trials are required to establish the role of MMF in these disorders.

Keywords: focal segmental glomerulosclerosis; minimal change nephropathy; mycophenolate mofetil; nephrotic syndrome

Notes

Correspondence and offprint requests to: Dr D. Adu, Department of Nephrology, Queen Elizabeth Hospital, Birmingham B15 2TH, UK. Email: dwoms{at}aol.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
A. Nakajo, J. Khoshnoodi, H. Takenaka, E. Hagiwara, T. Watanabe, H. Kawakami, R. Kurayama, Y. Sekine, F. Bessho, S. Takahashi, et al.
Mizoribine Corrects Defective Nephrin Biogenesis by Restoring Intracellular Energy Balance
J. Am. Soc. Nephrol., September 1, 2007; 18(9): 2554 - 2564.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
A. Segarra, M L. Amoedo, J. M Martinez Garcia, S. Pons, M. Praga, E. I. Garcia, J. C. Alonso, J. M. Gasco, L. Pou, and L. Piera
Efficacy and safety of 'rescue therapy' with mycophenolate mofetil in resistant primary glomerulonephritis--A multicenter study
Nephrol. Dial. Transplant., May 1, 2007; 22(5): 1351 - 1360.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
M. Waldman, R. J. Crew, A. Valeri, J. Busch, B. Stokes, G. Markowitz, V. D'Agati, and G. Appel
Adult Minimal-Change Disease: Clinical Characteristics, Treatment, and Outcomes
Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 445 - 453.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
P. M. Stassen, C. G. M. Kallenberg, and C. A. Stegeman
Use of mycophenolic acid in non-transplant renal diseases
Nephrol. Dial. Transplant., April 1, 2007; 22(4): 1013 - 1019.
[Full Text] [PDF]

Home page
 CJASNHome page
R. J. Hogg, L. Fitzgibbons, J. Bruick, M. Bunke, B. Ault, N. Baqi, H. Trachtman, and R. Swinford
Mycophenolate Mofetil in Children with Frequently Relapsing Nephrotic Syndrome: A Report from the Southwest Pediatric Nephrology Study Group
Clin. J. Am. Soc. Nephrol., November 1, 2006; 1(6): 1173 - 1178.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
F. Nakhoul, R. Ramadan, E. Khankin, A. Yaccob, Z. Kositch, M. Lewin, S. Assady, and Z. Abassi
Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: different effects of antiproteinuric therapies
Am J Physiol Renal Physiol, October 1, 2005; 289(4): F880 - F890.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
S. Troyanov, C. A. Wall, J. A. Miller, J. W. Scholey, D. C. Cattran, and for the Toronto Glomerulonephritis Registry Group
Focal and Segmental Glomerulosclerosis: Definition and Relevance of a Partial Remission
J. Am. Soc. Nephrol., April 1, 2005; 16(4): 1061 - 1068.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.